UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000020907
Receipt No. R000024123
Scientific Title The influence of sialidase on the management renal anemia therapy in CKD patients
Date of disclosure of the study information 2016/05/01
Last modified on 2020/02/12 (Ver. 7)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title The influence of sialidase on the management renal anemia therapy in CKD patients
Acronym SMART-CKD
Scientific Title The influence of sialidase on the management renal anemia therapy in CKD patients
Scientific Title:Acronym SMART-CKD
Region
Japan

Condition
Condition chronic kidney disease
Classification by specialty
Nephrology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To investigate the influence of sialidase activity on erythropoiesis stimulatory agent- resistant anemia in chronic kidney disease patients.
Basic objectives2 Pharmacodynamics
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes 1. Association of slilidase activity with estimated glomerular filtration ratio
2. Association of slilidase activity with hemoglobin level
3. Association of slilidase activity with usage and dosage of erythropoiesis stimulatory agent
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
90 years-old >=
Gender Male and Female
Key inclusion criteria Chronic kidney disease patients
Age over 20 to 90 years
Key exclusion criteria Infectious disease
neoplasm
bleeding complications
dementia
Target sample size 1400

Research contact person
Name of lead principal investigator
1st name Nobuhiko
Middle name
Last name Joki
Organization Toho University Ohashi Medical Center
Division name Division of Nephrology
Zip code 1538515
Address 2-17-6, Ohashi, Meguro-ku, Tokyo 153-8515, Japan
TEL +81-3-3468-1251
Email jokinobuhiko@gmail.com

Public contact
Name of contact person
1st name Nobuhiko
Middle name
Last name Joki
Organization Toho University Ohashi Medical Center
Division name Division of Nephrology
Zip code 1538515
Address 2-17-6, Ohashi, Meguro-ku, Tokyo 153-8515, Japan
TEL +81-3-3468-1251
Homepage URL
Email jokinobuhiko@gmail.com

Sponsor
Institute Toho University Ohashi Medical Center
Institute
Department

Funding Source
Organization Toho University
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor Toho University Omori Medical Center
Saiseikai Yokohama-City Eastern Hospital
Saitama Sekishinkai Hospital
Sayama jin clinic
Chugai Pharmaceutical Co., Ltd.


Name of secondary funder(s)

IRB Contact (For public release)
Organization Toho University Ohashi Medical Center
Address 2-17-6, Ohashi, Meguro-ku, Tokyo 153-8515, Japan
Tel 0334681251
Email jokinobuhiko@gmail.com

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2016 Year 05 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled 382
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2015 Year 12 Month 18 Day
Date of IRB
2016 Year 04 Month 30 Day
Anticipated trial start date
2016 Year 05 Month 01 Day
Last follow-up date
2019 Year 09 Month 30 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information 138 patients have been enrolled into the study

Management information
Registered date
2016 Year 02 Month 06 Day
Last modified on
2020 Year 02 Month 12 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000024123